19630 Investors following Dr Reddys Labs. Share this News with them.
0
Like this story, share it with millions of investors on M3
Dr Reddys Laboratories a market performer: Karvy
Karvy Stock Broking has downgraded its rating on Dr Reddys Laboratories to market performer with a target price of Rs 715. Dr. Reddy's Laboratories Limited (DRL) revenues have grown by 25 % to Rs 15037 million.
Karvy Stock Broking has downgraded its rating on Dr Reddys Laboratories to market performer with a target price of Rs 715 in its July 23, 2008 research report. "Dr. Reddy's Laboratories Limited (DRL) revenues have grown by 25 % to Rs 15037 million. The key growth drivers have been PSAI(Pharmaceutical Services & Active Ingredients) which has grown by 27 % to Rs 4613 million. The company has regrouped API and CPS segments as PSAI while North America Global generics has grown by 62 %. The growth in North America has been aided by the acquisition of the Shreveport facility. Gross margins have been marginally lower at 50.3 % while profits before forex gain has lower by 22% to Rs 1200 million."
"The company has reiterated its revenue guidance of 25 % revenue growth in rupee terms. As a result of the amortization charges and increased tax rates we downgrade our EPS estimates for FY 2009 by 7.1 % to Rs 38.5 and by 10.2 % to Rs 44.8. We downgrade our price target by 10.5% to Rs 715 based on 16x FY 2010E. As a result of the downgrade in price target we reduce our rating on the stock to Market Performer," says Karvy's research report.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
